- Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
- Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
- Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
- Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
Key statistics
On Friday, Immutep Ltd (IMM:ASX) closed at 0.435, -4.40% below its 52-week high of 0.455, set on Apr 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.42 |
---|---|
High | 0.445 |
Low | 0.42 |
Bid | 0.465 |
Offer | 0.405 |
Previous close | 0.42 |
Average volume | 3.69m |
---|---|
Shares outstanding | 1.19bn |
Free float | 1.14bn |
P/E (TTM) | -- |
Market cap | 499.31m AUD |
EPS (TTM) | -0.0394 AUD |
Data delayed at least 20 minutes, as of May 03 2024 06:59 BST.
More ▼